Eli Lilly (LLY) Short term Debt (2009 - 2026)

Eli Lilly (LLY) has reported Short term Debt for 18 consecutive years, with $4.0 billion the latest figure, recorded in Q1 2026.

• Short term Debt for Q1 2026 came in at $4.0 billion, changed 0.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 billion (changed 0.41% YoY), and the FY2025 annual result was $1.6 billion, down 68.05% from the prior year.
• Short term Debt was $4.0 billion for Q1 2026 at Eli Lilly, up from $1.6 billion in the prior quarter.
• Over five years, Short term Debt peaked at $6.9 billion in Q4 2023 and troughed at $3.1 million in Q1 2023.
• Average Short term Debt over 5 years is $2.8 billion, with a median of $2.1 billion recorded in 2024.
• Year-over-year, Short term Debt plunged 99.77% in 2023 and jumped 53174.19% in 2024.
• Over 5 years, Short term Debt stood at $1.5 billion in 2022, then surged by 359.96% to $6.9 billion in 2023, then declined by 25.89% to $5.1 billion in 2024, then slumped by 68.05% to $1.6 billion in 2025, then soared by 144.65% to $4.0 billion in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $4.0 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.